The full service PR and communications agency Cr Kommunikation “CRK” joins the Myty Group as the second Swiss agency after The House from Zurich. The agency network grows to a total of six agencies in
Tags :Vischer
Bachem Holding, an innovation-driven company specializing in the development and manufacture of peptides and oligonucleotides, has raised CHF 583.5 million through an accelerated bookbuilding process by issuing 750,000 new shares at a placement price of CHF 778 per
CombiGene and Spark Therapeutics, a member of the Roche Group and a fully integrated, commercial gene therapy company dedicated to the fight against genetic diseases, have entered into an exclusive collaboration and licensing agreement for
Vischer advised an insurance company and its London-based lawyers in an arbitration revolving around a power plant in South America. The dispute between the manufacturer of the plant and the insurer as the legal successor
Nautilus, an innovation specialist in home fitness, has entered into a definitive agreement to acquire Zurich based Vay, a company specialising in computer vision and AI technology solutions and the provider of motion detection and
Tvs Motor Company, an Indian based global two-wheeler and three-wheeler manufacturer and the flagship company of the USD 8.5 billion TVS Group, has agreed on a long-term strategic a partnership with Ego Movement, a fast-growing Swiss
Anjarium Biosciences, a Swiss biotech company, recently closed a CHF 55.5 million (USD 61 million) Series A financing round, co-led by Gimv and Abingworth. The fundraising also saw significant participation from Omega Funds, Pfizer Ventures and surveyor
Novaremed, a privately held clinical-stage biopharmaceutical company, expands its pipeline of non-opioid treatment candidates for chronic pain indications through the acquisition of Metys Pharmaceuticals. The acquisition broadens Novaremed’s existing pipeline by adding both
EnBiotix, a Boston-based biotech company focused on rare diseases, is merging with Swiss oncology and antimicrobial resistance-focused company Polyphor. A merger agreement under which Polyphor will use all of EnBiotix’s outstanding share capital in
Combioxin, a clinical phase biotechnology company based in Epalinges, Switzerland, has signed a worldwide commercial license agreement with Eagle Pharmaceuticals, a fully integrated pharmaceutical company based in Woodcliff Lake, NY, USA. Under the terms of
